Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 30
- Registration Number
- NCT04370795
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT04339777
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT04282174
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04220008
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 333
- Registration Number
- NCT04217278
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧Manchester Royal Infirmary, Manchester, United Kingdom
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Robert Lowsky
- Target Recruit Count
- 7
- Registration Number
- NCT04151706
- Locations
- 🇺🇸
Stanford Medical Center, Stanford, California, United States
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04127721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 823
- Registration Number
- NCT04009525
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04002115
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.